Slingshot members are tracking this event:
Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Oct 04, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Vk280, Vk2809, Hypercholesterolemia, Nafld